KonoSuba: Fantastic Days Celebrates Its First Anniversary With a 4 Star Legendary Festival Event
15.9.2022 04:02:00 EEST | Business Wire | Press release
KonoSuba: Fantastic Days, Nexon’s free-to-play mobile RPG, kicks off a two week celebration in honor of the game’s first anniversary. After battling for the last twelve months to defeat the villainous Devil King, our diligent heroes have earned the right to celebrate in festival events featuring premium gifts and rewards!
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220823005361/en/
#Nexon #NexonAmerica #KonoSuba (Graphic: Business Wire)
On top of the generous pre-registration bonuses offered earlier this month, and capping off a truly remarkable year in the world of Axel, KonoFans can expect a bounty of rewarding activities and gifts for their time spent in-game:
- 1st Anniversary Login Bonus (8/23 - 9/11): Free 10x Draw Ticket, up to 3000 Quartz, and more!
- New Main Quest and New Main Story (Part 2, Chapter 8)
-
New Story Event: “A Duet with This Crimson Demon Girl!”
- Players can experience Kazuma and Megumin's duet, "Bad Apple," during this event
- Participating in event missions allow you to get 3★ Lia (Dancing Announcer) for free!
-
1st Anniversary Ticket Draw (8/25 - 9/4):
- Tickets can be acquired from the 1st Anniversary Ticket Present event (8/16 - 8/29)
- Offers a chance to win 100,000 Quartz, 4★ Guaranteed Ticket, and more!
-
1st Anniversary Free 10x Recruit (8/23 - 9/3):
- Tickets can be acquired from 1st Anniversary related events/campaigns
- Offers a chance to get 1st Anniversary characters for free
-
1st Anniversary Legendary Adventurer Festival Recruit:
- Special Members
- 4★ Kazuma (Stage For Two)
- 4★ Megumin (Singing Sensation)
- Legendary Adventurer Festival Members
- 4★ Aqua (Legendary Adventurer)
- 4★ Darkness (Legendary Adventurer)
Based on the hit comedy anime series of the same name, KonoSuba: Fantastic Days was launched globally on August 19, 2021, on iOS and Android devices, after a successful release in Japan. The game focuses on a high school student (Kazuma) reincarnated to a fantasy world, where he is joined by a useless goddess (Aqua), an explosion fanatic (Megumin), and an unhinged crusader (Darkness) in their quest to fight the Devil King. Following the original storyline, the anime-based mobile title features brand new story content and exclusive heroes and heroines created specifically for the game. KonoFans have been able to battle as their favorite characters from the anime, all voiced by the original Japanese actors, including Jun Fukushima, Sora Amamiya, Rie Takahashi, and Ai Kayano.
Come celebrate in the wonderful, fantastical world of Axel!
KonoSuba: Fantastic Days is published by Nexon in partnership with KonoSuba publisher Kadokawa, and developed by Sumzap.
To stay up-to-date on KonoSuba: Fantastic Days, visit the Google Play or App Store page, and be sure to follow @PlayKonoSuba on Instagram and Twitter for the latest news!
Assets: Image Asset
Social Media: Twitch / Twitter / Instagram / Discord / Facebook
About KonoSuba: Fantastic Days konosuba.nexon.com
Based on the popular anime series “KonoSuba: God's Blessing on this Wonderful World!”, KonoSuba: Fantastic Days is a free-to-play character-collection RPG for iOS and Android. Featuring fan-favorite characters, including Kazuma Satou, Aqua, Megumin and Darkness, the game follows the storyline from the original novel and includes bespoke characters created exclusively for the game. Last year, the Japanese release of KonoSuba: Fantastic Days saw great success, garnering recognition from players and praise from the KonoSuba fan base.
About Nexon America Inc. https://www.nexon.com/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220823005361/en/
Contact information
Brian Klotz
Nexon America
NA_pr@nexon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Owl Labs partners with Westcoast to expand access to seamless hybrid meeting experiences in the UK and Ireland11.5.2026 10:00:00 EEST | Press release
Owl Labs, a global leader in AI-powered, 360-degree video conferencing solutions, today announced a new UK and Ireland distribution partnership with Westcoast Limited, one of the country’s largest and most trusted IT distributors. The agreement will see Westcoast distribute the full range of Owl Labs’ award-winning Meeting Owl and Owl Bar products across the UK and Ireland, providing greater choice, availability, and dedicated support for resellers and end customers navigating the demands of hybrid work. The partnership aims to address the technical setup challenges that plague meetings across the UK. Owl Labs’ recent State of Hybrid Work report found that nearly 8 in 10 workers (79%) lose time in meetings due to technical difficulties such as connecting to a meeting or setting up a camera. By making Owl Labs’ solutions simpler to source, deploy and support, the Westcoast partnership helps cut the ‘meeting tax’, reducing set‑up friction and getting meetings started on time. The announc
Kiabi Selects Navan to Centralise Global Travel Program11.5.2026 10:00:00 EEST | Press release
Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced it has been selected by Kiabi, the French multinational fashion retailer, to consolidate its global travel with one unified platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511547434/en/ Fashion retailer targets high employee adoption and efficiency with AI-powered travel platform To support its workforce of nearly 10,000 “Kiabers,” the retailer required a solution capable of providing an easy-to-use travel platform. Navan was selected due to its intuitive AI-powered interface and ability to integrate with Kiabi’s travel policies directly in-app. “Managing travel was becoming an administrative burden that slowed our teams down,” said Denise Maurice, Indirect Procurement Director at Kiabi. “We wanted to give our ‘Kiabers’ the freedom to book their own trips without getting bogged down in manual approvals. Navan gives t
Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G pTau 217 Plasma Assay11.5.2026 10:00:00 EEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Fujirebio Europe N.V. has obtained a CE certificate of the Lumipulse G pTau 217 Plasma assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human plasma (K2EDTA). “With Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma now CE‑marked on our LUMIPULSE G platform, we are advancing a new era of neurology diagnostics—one where blood‑based biomarkers enable earlier, broader, and more accessible insights into Alzheimer’s disease and neurodegeneration.” said Christiaan De Wilde, CEO at Fujirebio Europe N.V. “By delivering fully automated and scalable solutions, we are helping clinicians move decisively toward more timely and informed decision‑making. This milestone underscores our long‑term vision to reimagine the diagnostic
Mevion Introduces the First Proton Therapy System Designed for a LINAC Vault at ESTRO 202611.5.2026 09:00:00 EEST | Press release
Proton therapy is entering the LINAC vault. At ESTRO 2026, Mevion Medical Systems will introduce the MEVION S250-FIT Proton Therapy System to the European radiation oncology community, the first proton therapy system designed for installation in a standard radiation therapy vault. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507172087/en/ The MEVION S250-FIT™ Proton Therapy System Now both U.S. FDA-cleared and CE-marked under Regulation (EU) 2017/745, the S250-FIT creates a new pathway for cancer centers to bring proton therapy into existing LINAC-based treatment environments, aligning advanced proton capability with the infrastructure, workflows, and capital planning of modern radiation oncology. Stanford Medicine: First S250-FIT Installation On April 7, 2026, Stanford Medicine unveiled the world’s first S250-FIT installation, developed in collaboration with Leo Cancer Care. The system was fully installed within a stan
CORRECTING and REPLACING Samsung Epis Holdings Reports First Quarter 2026 Financial Results11.5.2026 08:10:00 EEST | Press release
Business Updates section, the first bullet of release dated April 23, 2026, at 10:04 p.m. PT/April 24, 2026, at 1:04 a.m. ET should read: In October 2025, Samsung Bioepis entered into a private label partnership with Cordavis for OSPOMYV™ (denosumab-dssb), a biosimilar to Prolia1. The updated release reads: SAMSUNG EPIS HOLDINGS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026. “Samsung Bioepis delivered solid growth this quarter driven by continued momentum across our biosimilar portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are further strengthening our position through new global partnerships and continued portfolio expansion. As we mark the 10th anniversary of the launch of our first biosimilar in Europe, we remain focused on b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom